Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus CHLOROPTIC S O P.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus CHLOROPTIC S O P.
CHLOROMYXIN vs CHLOROPTIC S.O.P.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
Apply 0.5-inch ribbon into the conjunctival sac(s) 1-2 times daily, or more frequently as directed.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
Terminal half-life approximately 4-6 hours; clinical context: dosing every 4-6 hours for ocular infections
CHLOROMYXIN is not a recognized drug. No data available.
Renal (70-80% as unchanged drug and metabolites), biliary/fecal (20-30%)
Category C
Category C
Antibiotic
Antibiotic